These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 28162910)

  • 1. Direct Effects of Anti-Angiogenic Therapies on Tumor Cells: VEGF Signaling.
    Simon T; Gagliano T; Giamas G
    Trends Mol Med; 2017 Mar; 23(3):282-292. PubMed ID: 28162910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
    Shojaei F; Ferrara N
    Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives.
    Lopes-Coelho F; Martins F; Pereira SA; Serpa J
    Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33916438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF signaling in cancer treatment.
    Sia D; Alsinet C; Newell P; Villanueva A
    Curr Pharm Des; 2014; 20(17):2834-42. PubMed ID: 23944367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Redundant angiogenic signaling and tumor drug resistance.
    Gacche RN; Assaraf YG
    Drug Resist Updat; 2018 Jan; 36():47-76. PubMed ID: 29499837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting vasculogenic mimicry by phytochemicals: A potential opportunity for cancer therapy.
    Haiaty S; Rashidi MR; Akbarzadeh M; Maroufi NF; Yousefi B; Nouri M
    IUBMB Life; 2020 May; 72(5):825-841. PubMed ID: 32026601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modes of resistance to anti-angiogenic therapy.
    Bergers G; Hanahan D
    Nat Rev Cancer; 2008 Aug; 8(8):592-603. PubMed ID: 18650835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [VEGF in neoplastic angiogenesis].
    Chekhonin VP; Shein SA; Korchagina AA; Gurina OI
    Vestn Ross Akad Med Nauk; 2012; (2):23-33. PubMed ID: 22642175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycosylation as new pharmacological strategies for diseases associated with excessive angiogenesis.
    Bousseau S; Vergori L; Soleti R; Lenaers G; Martinez MC; Andriantsitohaina R
    Pharmacol Ther; 2018 Nov; 191():92-122. PubMed ID: 29909237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Endoglin for tumor imaging and targeted cancer therapy.
    Paauwe M; ten Dijke P; Hawinkels LJ
    Expert Opin Ther Targets; 2013 Apr; 17(4):421-35. PubMed ID: 23327677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LHT7, a chemically modified heparin, inhibits multiple stages of angiogenesis by blocking VEGF, FGF2 and PDGF-B signaling pathways.
    Chung SW; Bae SM; Lee M; Al-Hilal TA; Lee CK; Kim JK; Kim IS; Kim SY; Byun Y
    Biomaterials; 2015 Jan; 37():271-8. PubMed ID: 25453957
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
    Itatani Y; Kawada K; Yamamoto T; Sakai Y
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
    Li C; Liu T; Bazhin AV; Yang Y
    J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic.
    Ye W
    Dev Cell; 2016 Apr; 37(2):114-25. PubMed ID: 27093081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies.
    Bottsford-Miller JN; Coleman RL; Sood AK
    J Clin Oncol; 2012 Nov; 30(32):4026-34. PubMed ID: 23008289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
    Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
    Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the tumor stroma in cancer therapy.
    Anton K; Glod J
    Curr Pharm Biotechnol; 2009 Feb; 10(2):185-91. PubMed ID: 19199950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
    Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
    Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.